Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core
Source: SeekingAlpha
2025-10-29 13:38:23 ET
Overview
Akebia Therapeutics’ stock ( AKBA ) is reeling following the announcement that it intends not to pursue VALOR or a broad U.S. non-dialysis (NDD) label for Vafseo....
Read the full article on Seeking Alpha
For further details see:
Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core
Akebia Therapeutics Inc.
NASDAQ: AKBA
AKBA Trading
1.1% G/L:
$1.375 Last:
1,228,536 Volume:
$1.38 Open:
AKBA Latest News
March 03, 2026 08:00:00 am
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026 07:00:00 am
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
AKBA Stock Data
$399,375,819
257,405,013
0.93%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
